- Home
- SLGL vs CING Comparison
SLGL vs CING Comparison
Compare SLGL & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLGL
- CING
- Stock Information
- Founded
- SLGL 1997
- CING 2012
- Country
- SLGL Israel
- CING United States
- Employees
- SLGL N/A
- CING N/A
- Industry
- SLGL Biotechnology: Pharmaceutical Preparations
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- SLGL Health Care
- CING Health Care
- Exchange
- SLGL Nasdaq
- CING Nasdaq
- Market Cap
- SLGL 17.0M
- CING 14.4M
- IPO Year
- SLGL 2018
- CING 2021
- Fundamental
- Price
- SLGL $0.58
- CING $4.27
- Analyst Decision
- SLGL Strong Buy
- CING Strong Buy
- Analyst Count
- SLGL 2
- CING 3
- Target Price
- SLGL $5.00
- CING $16.00
- AVG Volume (30 Days)
- SLGL 62.4K
- CING 118.1K
- Earning Date
- SLGL 03-12-2025
- CING 03-31-2025
- Dividend Yield
- SLGL N/A
- CING N/A
- EPS Growth
- SLGL N/A
- CING N/A
- EPS
- SLGL N/A
- CING N/A
- Revenue
- SLGL $11,707,000.00
- CING N/A
- Revenue This Year
- SLGL $772.97
- CING N/A
- Revenue Next Year
- SLGL N/A
- CING N/A
- P/E Ratio
- SLGL N/A
- CING N/A
- Revenue Growth
- SLGL 869.93
- CING N/A
- 52 Week Low
- SLGL $0.33
- CING $1.80
- 52 Week High
- SLGL $1.65
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- SLGL 37.73
- CING 42.05
- Support Level
- SLGL $0.56
- CING $4.22
- Resistance Level
- SLGL $0.61
- CING $4.58
- Average True Range (ATR)
- SLGL 0.07
- CING 0.32
- MACD
- SLGL -0.01
- CING -0.04
- Stochastic Oscillator
- SLGL 12.00
- CING 12.64
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.